How is the pharmaceutical industry reacting to the FDA’s surprising approval of a controversial Alzheimer’s drug, and what do they make of its $56,000 price tag?

This is the last episode in our weeklong series examining the potentially sweeping consequences this drug, known as aducanumab, could have on millions of patients’ lives and billions of dollars in health care spending.

Guest:

Luke Timmerman, Journalist/Founder, Timmerman Report

Explore the full series and additional resources: https://tradeoffs.org/aducanumab

Read a transcript of this episode: https://tradeoffs.org/2021/06/25/the-aducanumab-aftermath-the-industry/

Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: bit.ly/tradeoffsnewsletter

Support this type of journalism today, with a gift: https://tradeoffs.org/donate

Follow us on Twitter: https://twitter.com/tradeoffspod

Hosted on Acast. See acast.com/privacy for more information.